|
|
| JKAL,Neves; S,Sarinho; CML,de Melo; VRA,Pereira; MCA,de Lima; IR,Pitta; MCPA,Albuquerque; SL,Galdino. |
| Schistosomiasis is a major public health problem with 207 million people infected and more than 779 million at risk. The drug of choice for treating schistosomiasis is praziquantel (PZQ); however, it is inefficient against immature forms of schistosomes. The aim of this study was to test new imidazolidine derivatives LPSF/PT09 and LPSF/PT10 against adult Schistosoma mansoni worms. IC50, cytotoxicity, immune response and cell viability assays were also available for these imidazolidines. Different concentrations of imidazolidine, from 32 to 320 ¼M, promoted motor abnormalities in breeding and unpaired worms, and death in 24 hours at higher concentrations. Although LPSF/PT09 and LPSF/PT10 did not affect IFN-³ and IL-10 production, they induced nitric oxide... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Schistosoma mansoni; In vitro; Imidazolidines. |
| Ano: 2011 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1678-91992011000300007 |
| |
